Loading
Life sciences · Journal article
Journal of Medicinal Chemistry · November 5, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Dual targeting of poly(ADP-ribose) polymerase (PARP) and the colchicine-binding site (CBS) of tubulin represents a promising strategy to overcome tumor heterogeneity and acquired resistance. Herein, a series of benzofused heterocyclic carboxamide derivatives were designed and synthesized as novel dual PARP/CBS inhibitors. Structure−activity relationship studies identified D13 as the most potent lead, demonstrating low-nanomolar antiproliferative activities (IC50 = 2−15 nM) across multiple cancer cell lines with high selectivity over normal cells. D13 inhibited PARP1/2 enzymatic activity and suppressed tubulin polymerization via CBS binding. D13 also induced G2/M arrest, DNA damage, and apoptosis, while blocking cell migration and tube formation. In an MDA-MB-231 xenograft model, D13 at 20 mg/kg achieved 72.3% tumor growth inhibition with dose-dependent efficacy and good tolerability, outperforming veliparib, phenstatin, and their combination. These findings validate dual PARP/CBS inhibition as a viable therapeutic strategy and support further development of D13 as an anticancer lead.